Keywords: Prostate, Cancer, Metabolomics, metabolomic imaging, nuclear magnetic resonance, spectroscopy, prostate cancer, MRI-US fusion, biopsy
Motivation: Evaluations of prostate cancer (PCa) with traditional transrectal ultrasound (TRUS) and multiparametric MRI-ultrasound (mpMRI-US) fusion biopsies may produce false-positives or false-negatives, thereby preventing optimal and timely treatments.
Goal(s): To evaluate PCa metabolomics from TRUS and fusion biopsy cores using magnetic resonance spectroscopy (MRS) to identify potential metabolomic biomarkers for better characterization of PCa.
Approach: Using ex vivo MRS, we measured 432 prostate biopsy cores from patients suspicious of PCa between 4/2006 and 10/2018.
Results: MRS metabolomics could differentiate between benign and malignancy, reflect malignant status from benign cores, and allowed for predictions of future PCa from benign biopsies.
Impact: Our results demonstrate that MRS-based metabolomic evaluations have the potential to detect PCa years earlier than standard TRUS and fusion biopic techniques, and improve PCa active surveillance based on prostate biology.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords